New potential of ACE inhibitors in clinical practice
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
The paper reviews the results of the studies demonstrating new potential of ACE inhibitors. The traditional clinical niche for ACE inhibitor therapy (arterial hypertension, heart failure, diabetic nephropathy) has been extended recently. Substantial vasoprotective effect of these medications has an important role in decelerating progression of atherosclerotic cardiovascular pathology. In addition, a differential assessment of protective effects, together with prognosis improvement among high-risk patients, is presented for various ACE inhibitors.
About the Authors
D. V. Nebieridze
State Research Centre for Preventive Medicine. Moscow
Russian Federation
Russian Federation
A. S. Safaryan
State Research Centre for Preventive Medicine. Moscow
Russian Federation
Russian Federation
References
1. Tretii peresmotr rekomendatsii VNOK i RMOAG po diagnostike i lecheniyu arterial'noi gipertenzii. Kardiovask ter profil 2008; 4 (3) ch.1: 105-20.
2. Natsional'nye rekomendatsii VNOK i OSSN po diagnostike i lecheniyu KhSN (vtoroi peresmotr). Serd nedostat 2006; 8(2): 1-35.
3. CAPPP Hansson L, Lindholm LH, Niskanen L et al: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomized trial. Lancet 1999; 353: 611-6.
4. Bonner G, Preis S, Schunck U, et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 1990; 15 (Suppl 6): 46-56.
5. Busse R, Lamontagne D. Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensinconverting enzyme inhibitors in human endothelial cells. Naunyn-Schmiedebergs Arch Pharmacol 1991; 344: 126-9.
6. Anderson TJ, Overhiser RW, Haber H, Charbonneau F. A comparative study of four anti-hypertensive agents on endothelial function in patients with coronary disease. JACC 1998; 31 (2, Suppl A): 32-7. Abstract.
7. Whitebread S, Mele M, Kamber B, de Gasparo M. Preliminary biochemical characterization of two angiotension II receptor subtypes. Biochemic Biophys Res Commun 1989; 163: 284-91.
8. NOPE study investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
9. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomased, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
10. PEASE Trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.
11. Nissen SE, Tuscu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary artery disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-26.
12. Diagnostika i lechenie stabil'noi stenokardii. V sbornike Natsional'nykh klinicheskikh rekomendatsii pod redaktsiei akad. R.G.Oganova. Moskva 2009; 331-82.
13. Lonn EM, Yusuf S Dzavic V, et al. Effects of ramipril and vitamin E on atherosclerosis: treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-25.
14. 2007 Guidelines for the management of Arterial hypertension. J Hypertens 2007; 25: 1105-87.
15. HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
16. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcome in hypertensive nephrosclerosis. JAMA 2001; 285: 2719-28.
Review
For citations:
Nebieridze D.V., Safaryan A.S. New potential of ACE inhibitors in clinical practice. Cardiovascular Therapy and Prevention. 2010;9(5):91-94. (In Russ.)
Views:
521
ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)
ISSN 2619-0125 (Online)
Email this article 
